Trial Profile
A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 26 Jan 2021 Planned End Date changed from 1 Aug 2021 to 18 Aug 2021.
- 26 Jan 2021 Planned primary completion date changed from 1 Aug 2021 to 18 Aug 2021.
- 05 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.